| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden targets pathways involved in oxidative stress and inflammation as a flavonoid glycoside. As a derivative of quercetin, it may have antioxidant, anti-inflammatory, and anticancer activities. The compound's multiple sugar moieties may affect its bioavailability and cellular uptake. Its mechanism involves modulation of signaling pathways through its flavonoid structure. Further studies are needed to fully characterize its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden is a flavonoid from Quercetin. It is a biflavonoid glycoside. The compound is soluble in DMSO. Its purity is >98% by HPLC. As a flavonoid glycoside, it may exhibit antioxidant, anti-inflammatory, and anticancer activities. Its bioactivity has been characterized in various cell-based assays. Further in vitro studies are needed to fully characterize its pharmacological effects.
|
| ln Vivo |
In vivo, Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden has potential applications as a flavonoid glycoside. As a derivative of quercetin, it may have antioxidant, anti-inflammatory, and anticancer activities. The compound is a natural product from quercetin. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro enzyme assays for Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden involve measuring its antioxidant and anti-inflammatory activities. Antioxidant activity is assessed using DPPH, ABTS, or other free radical scavenging assays. Anti-inflammatory activity is measured by assessing inhibition of pro-inflammatory cytokine production or COX/LOX activity. Enzyme inhibition assays may be performed to identify specific molecular targets. Assays are performed in appropriate buffer systems with positive controls such as known flavonoids.
|
| Cell Assay |
In vitro cell-based assays for Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden are conducted in various cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Antioxidant activity is assessed by measuring intracellular ROS levels. Anti-inflammatory activity is assessed by measuring cytokine levels by ELISA. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden in vivo studies are conducted in animal models of oxidative stress and inflammation. Animals are treated with the compound via oral administration or injection. Oxidative stress markers and inflammatory markers in blood and tissues are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden (MW 788.66 g/mol, C33H40O22) is a flavonoid glycoside. It is soluble in DMSO. The compound has a purity of >98% by HPLC. It is a natural product derived from quercetin. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden is generally well-tolerated in preclinical studies. The compound is a natural flavonoid glycoside with established safety profiles. Its antioxidant and anti-inflammatory activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiglycoside is a glycoside of flavonoids.
Quercetin-3-O-β-D-glucose-7-O-β-D-gentiobiosiden is a biflavonoid glycoside derived from quercetin. It is a flavonoid from Quercetin. The compound has antioxidant, anti-inflammatory, and potential anticancer activities. Its molecular formula is C33H40O22 with a molecular weight of 788.66 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C33H40O22
|
|---|---|
| Molecular Weight |
788.6575
|
| Exact Mass |
788.201
|
| CAS # |
60778-02-1
|
| PubChem CID |
131637041
|
| Appearance |
White to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
1189.6±65.0 °C at 760 mmHg
|
| Flash Point |
371.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.776
|
| LogP |
-1.89
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
55
|
| Complexity |
1340
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O
|
| InChi Key |
VUTMUSRYWYUQIK-GZIDCZEMSA-N
|
| InChi Code |
InChI=1S/C33H40O22/c34-6-15-19(39)23(43)26(46)31(52-15)49-8-17-21(41)25(45)27(47)32(54-17)50-10-4-13(38)18-14(5-10)51-29(9-1-2-11(36)12(37)3-9)30(22(18)42)55-33-28(48)24(44)20(40)16(7-35)53-33/h1-5,15-17,19-21,23-28,31-41,43-48H,6-8H2/t15-,16-,17-,19-,20-,21-,23+,24+,25+,26-,27-,28-,31-,32-,33+/m1/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5-hydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~126.80 mM)
DMSO : ~100 mg/mL (~126.80 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (12.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (12.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2680 mL | 6.3399 mL | 12.6797 mL | |
| 5 mM | 0.2536 mL | 1.2680 mL | 2.5359 mL | |
| 10 mM | 0.1268 mL | 0.6340 mL | 1.2680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
